吉西他滨/卡铂和吉西他滨/顺铂方案治疗晚期非小细胞肺癌的疗效比较

目的 观察吉西他滨／卡铂（GCarb）和吉西他滨／顺铂（GCis）治疗晚期非小细胞肺癌（NSCLC）的疗效和毒副反应。方法 经病理和细胞学证实的40例晚期NSCLC患者随机分为两组。GCarb组给予吉西他滨1000mg/m^2静脉滴注，第1、8天；卡铂AUC4－6静脉滴注，第1天。GCis组给予吉西他滨1000mg/m^2静脉滴注，第1、8天，顺铂30－40mg/m^2静脉滴注，第1－3天。两组均21天为一周期，连续使用2－3周期评价疗效和毒副反应。结果 GCarb组有效率为65％，GCis组为60％，两组疗效无显著性差异（P＞0.5）。两组毒副反应依次为骨髓抑制、胃肠道反应、脱发和皮疹。GCarb组胃肠道反应低于GCis组（P＜0.05）。结论 GCarb和GCis均可作为NSCLC的一线治疗方案。

Comparison of efficacy and toxicity between gemcitabine plus carboplatin and gemcitabine plus cisplatin in the treatment of advanced non-small cell lung cancer

Objective To observe the efficacy and toxicity of gemcitabine plus carboplatin (GCarb) versus gemcitabine plus cisplatin (GCis) in the treatment of advanced non small cell lung cancer (NSCLC). Methods Forty patients with histologically confirmed NSCLC were randomized to enter the study. GCarb group:Gemcitabine 1 000 mg/m 2 IV on day 1,8; carboplatin AUC 4 6 IV on day 1. GCis group: Gemcitabine 1 000 mg/m 2 IV on day 1,8; cisplatin 30 40 mg/m 2 IV on day 1 3. Results The response rate was 65% and 60% for GCarb group and GCis group respectively (P>0.5). Toxicities included myelosuppression, digestive reaction, alopecia and rash. Digestive toxicity in GCarb group was less than that in GCis group (P<0.05). Conclusion Both GCarb and GCis regimes can be used as first line protocol in the chemotherapy of non small cell lung cancer.